Skip to content
StockMarketAgent
Direct answer
Merck is a mature cash-generator currently heavily reliant on its blockbuster oncology drug Keytruda and the Gardasil vaccine franchise. While near-term cash flows and dividend safety are robust, the long-term investment thesis hinges on management's ability to successfully commercialize its pipeline of Antibody-Drug Conjugates (ADCs) and leverage M&A to offset the massive patent cliff approaching in 2028. Fair value range: low $94.9, high $147, with mid-point at $121.
Stock analysis

MRK fair value $95–$147

By StockMarketAgent.AI team· supervised by
Analyzed: 2026-05-08Next update: 2026-08-08Methodology v2.5Review: automatedArchetype: Mature dividend
View archive
Last price
$112.30
▲ +8.31 (+7.40%)
Fair value
$121
$95–$147
Rating
Hold
confidence 84/100
Upside
+7.4%
upside to fair value
Margin of Safety
$102.52
MoS level · 15%
Market Cap
$277.4B
P/E fwd 11.8

§1 Executive summary

  • Heavy concentration risk in Keytruda, which faces loss of exclusivity in 2028.
  • Dependency on future M&A and ADC pipeline execution to replace lost revenue.
  • Primary valuation anchor focuses on near-term forward earnings over stale trailing cash flows.
Fair value
$121
Margin of safety
+6.9%
Confidence
84/100
Moat
9/10

Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.

$112.30Price
Low $94.87
Mid $120.61
High $146.75

Merck is a mature cash-generator currently heavily reliant on its blockbuster oncology drug Keytruda and the Gardasil vaccine franchise. While near-term cash flows and dividend safety are robust, the long-term investment thesis hinges on management's ability to successfully commercialize its pipeline of Antibody-Drug Conjugates (ADCs) and leverageLeverageThe proportion of debt in the company's capital structure. Commonly measured as Debt/EBITDA, Debt/Equity, or Net Debt/EBITDA. M&A to offset the massive patent cliff approaching in 2028.

  • Intangible Assets (Patents)
    Intangible Assets (Patents)
  • Economies of Scale
    Economies of Scale
  • Cycle upside
    Accelerating M&A and robust pipeline readouts across the biopharma sector.

§2 Bear case

A severe stress test assumes structural earnings decline post-2028 as Keytruda revenues drop, combined with a failure to realize ADC revenueRevenueRevenue is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions. and M&A integration issues, compressing gross margins.

Ways this thesis can break

Severe Keytruda Cliff

· High

Failure to offset Keytruda LOE through M&A or internal ADC pipeline leaves a massive revenue gap, severely compressing structural margins.

FV impact
Down to $94.87
Trigger
2028-2030

ADC Pipeline Failure

· Medium

Late-stage clinical failures in the Antibody-Drug Conjugate pipeline erode future growth vectors, stalling the dividend trajectory.

FV impact
Loss of terminal growth and multiple derating
Trigger
2026-2028

Draconian IRA Pricing

· Medium

Aggressive regulatory pricing pressures from the IRA compress margins more sharply than modeled, stunting near-term operating cash flows.

FV impact
Terminal margin deterioration
Trigger
2026-2029
Early-warning signals to monitor
MetricCurrentTrigger threshold
Slowdown in Keytruda quarterly sales growth pre-2028MonitorDeterioration versus the report thesis
Negative FDA decisions on late-stage ADC candidatesMonitorDeterioration versus the report thesis
Escalating R&D costs without proportional revenue gainsMonitorDeterioration versus the report thesis
Unfavorable shifts in gross margin trajectoriesMonitorDeterioration versus the report thesis
Management signaling a pause or slowing of dividend growthMonitorDeterioration versus the report thesis

§3 Financial history

Income statement — last six periods
Line itemT−0T−1T−2T−3CAGR
Period2022-12-312023-12-312024-12-312025-12-31Trend
Revenue$59.28B$60.12B$64.17B$65.01B+3.1%
Gross profit$41.87B$43.99B$48.98B$48.63B+5.1%
Operating income$18.28B$2.95B$20.22B$22.11B+6.5%
Net income$14.52B$365.0M$17.12B$18.25B+7.9%
EPS (diluted)$5.71$0.14$6.74$7.28+8.4%
EBITDA$21.32B$6.91B$25.71B$28.26B+9.9%
R&D$13.55B$30.53B$17.94B$15.79B+5.2%
SG&A$10.04B$10.50B$10.82B$10.73B+2.2%

Quality scores

Piotroski F-score
4 / 9
0–9 quality composite
Altman Z-score
3.87
Bankruptcy risk (>3 safe)
Beneish M-score
-2.27
Earnings manipulation risk
OCF / Net income
0.9×
>1 indicates high earnings quality
Accounting quality gate
Pass
Sector-adjusted gate
ROIC
17.4%
Return on invested capital
§3

Numbers analysis

Cash flow

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Capital allocation

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Individual subscribers — §4 onwards11 more sections

Read the full analysis — 11 more sections.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Full report for every covered ticker
24 months of rating archive
Watchlist briefings + rating-change alerts
PDF + DOCX export in any language
Start free trial
Cancel anytime.
INTRINSIC VALUE FAQ

MRK intrinsic value questions

  1. MRK (MRK)'s intrinsic value is triangulated from discounted earnings at two cost-of-equity levels (strict CAPM with raw beta, moderate with adjusted beta), with owner earnings used as a floor for high-growth names.

FAQ

MRK — frequently asked questions

  1. Based on our latest analysis, MRK looks modestly undervalued. The current price is $112 versus a composite fair-value midpoint of $121 (range $94.9–$147), which implies roughly 7.4% upside to the midpoint.

Related coverage

Names readers of MRK also follow

Same archetype: mature-dividend